Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 8, 2020

View Archived Issues

Normal tissue gives clues to bladder cancer's beginnings

Tarsus announces data from phase II studies of TP-03 in Demodex blepharitis

MANF regulation seen to control hepatic lipid accumulation in NAFLD

Three's a crowd: Doudna-Charpentier duo is sole winner of chemistry Nobel

Gilead Sciences patents new HIV antivirals

Novartis discloses mTORC1 inhibitors

Korean researchers present EGFR inhibitors

NOD1 as a potential new therapeutic target for saturated-fat induced insulin resistance

Stanford University synthesizes new PI4K inhibitors

Responses seen with famitinib plus camrelizumab in ovarian and cervical cancer

Phase I data for CEND-1 plus gemcitabine and nab-paclitaxel in metastatic PDAC

Moleculin's WP-1096 and WP-1097 show in vitro activity for HIV, Zika and dengue fever

Primary endpoints not met with first-line durvalumab +/- tremelimumab in urothelial carcinoma

Study indicates potential of bosutinib to treat neurodegenerative conditions

mRNA-1273 vaccine candidate shows safety and immunogenicity in older adults

Toripalimab plus chemotherapy efficacious in treating advanced biliary tract cancer

Phase III study of Gamida Cell's omidubicel meets all secondary endpoints

IDMC recommends piclidenoson psoriasis study continue, rheumatoid arthritis trial end

New phase I study evaluates cord blood-derived NK cells preloaded with AFM-13

Napo initiates pivotal trial of crofelemer for cancer therapy-related diarrhea

Lilly reports interim data on combination therapy with LY-CoV555 and LY-CoV016 for COVID-19

Preclinical data support therapeutic potential of Molecular's anti-COVID-19 DARPin candidates

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Deals and an M&A strengthen end-of-year numbers
BioWorld
Two large deals and an acquisition, totaling about $4.64 billion in all, are helping wrap up what’s turning out to be a strong year. Through the first 11 months...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Radiopharm Theranostics’ RAD-101 meets brain metastases endpoints
BioWorld
Radiopharm Theranostics Ltd.’s radiotracer RAD-101 met the primary endpoint in 92% of patients in the phase IIb imaging trial in brain metastases, according to...